^
    10d
    Specific depletion of TIGIThigh CD226- clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting. (PubMed, J Immunother Cancer)
    Targeted elimination of clonally expanded intratumoral Tregs is essential to unlock the full therapeutic potential of αTIGIT. These novel findings provide a key rationale and strategic direction for overcoming the limitations of current αTIGIT-based cancer immunotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • CD226 (CD226 Molecule)
    |
    tiragolumab (RG6058)
    16d
    Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov)
    P2, N=0, Withdrawn, National Cancer Institute (NCI) | N=36 --> 0 | Trial completion date: Jun 2027 --> Aug 2025 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2026 --> Aug 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    RAS wild-type
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    17d
    A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, M.D. Anderson Cancer Center | N=35 --> 4 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Checkpoint inhibition
    |
    CD4 (CD4 Molecule)
    |
    BostonGene Tumor Portrait™ Test
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    22d
    A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=199, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Jul 2026 --> Oct 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • axitinib • tiragolumab (RG6058) • tobemstomig (RG6139)
    29d
    SKYLINE: Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting | N=130 --> 81
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PD-L1 negative • ER negative
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • tiragolumab (RG6058)
    29d
    Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial. (PubMed, ESMO Gastrointest Oncol)
    Secondary endpoints include feasibility, safety, post-operative complications, and metabolic response by positron emission tomography. Exploratory studies characterize immune cell infiltration, tumor mutational burden, and circulating tumor DNA dynamics.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    1m
    SKYSCRAPER-15: A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (clinicaltrials.gov)
    P3, N=56, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    1m
    A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
    P1/2, N=518, Recruiting, Hoffmann-La Roche | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • IO-108 • imdatifan (NKT2152) • muzastotug (ADG126) • tobemstomig (RG6139)
    1m
    A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (clinicaltrials.gov)
    P1, N=542, Recruiting, Hoffmann-La Roche | Trial completion date: Nov 2028 --> Aug 2030 | Trial primary completion date: Aug 2027 --> Aug 2030
    Trial completion date • Trial primary completion date
    |
    FoundationOne® Liquid CDx
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • divarasib (RG6330) • Itovebi (inavolisib) • SY-5609 • tiragolumab (RG6058)
    1m
    A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (clinicaltrials.gov)
    P2, N=204, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    1m
    SKYSCRAPER-01: A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=620, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    1m
    Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Georgetown University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK wild-type • ROS1 wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)